{"company":{"id":3786159,"name":"Marea Therapeutics","domain":"mareatx.com","url":"https://alion.io/company/mareatx"},"section":"news","answer":"Marea Therapeutics: 18 headlines on record, 5 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"18"},{"label":"In 90 days","value":"5"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":14},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-10-05","kind":"Press release","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly","url":"https://mareatx.com/press-releases/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the-treatment-of-acr/"},{"date":"2026-09-18","kind":"Blog","title":"Marea Corporate Presentation","url":"https://mareatx.com/presentations/marea-corporate-presentation/"},{"date":"2026-09-17","kind":"Press release","title":"Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement","url":"https://mareatx.com/press-releases/lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement/"},{"date":"2026-06-25","kind":"Award","title":"San Francisco Business Times Best Places to Work 2026","url":"https://mareatx.com/in-the-news/san-francisco-business-times-best-places-to-work-2026/"},{"date":"2026-06-15","kind":"Press release","title":"Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026","source":"BioSpace","url":"https://biospace.com/press-releases/marea-therapeutics-presents-phase-1-data-supporting-potential-best-in-disease-profile-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026"},{"date":"2026-05-26","kind":"Press release","title":"Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026","url":"https://mareatx.com/press-releases/marea-therapeutics-to-present-data-from-phase-1-study-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026/"},{"date":"2026-01-13","kind":"Press release","title":"Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile","url":"https://mareatx.com/press-releases/marea-therapeutics-unveils-positive-topline-phase-1-data-for-mar002-in-acromegaly-demonstrates-potential-for-best-in-disease-efficacy-and-dosing-profile/"},{"date":"2026-01-05","kind":"Press release","title":"Marea Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://mareatx.com/press-releases/marea-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference/"},{"date":"2025-12-08","kind":"Blog","title":"2025 Global CVCT Forum: A Novel ANGPTL4 Inhibitory Antibody (MAR001) Safey Lowers Plasma Triglycerides and Remnant Cholesterol in Humans","url":"https://mareatx.com/publications-posters/2025-global-cvct-forum-a-novel-angptl4-inhibitory-antibody-mar001-safey-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans/"},{"date":"2025-08-12","kind":"Press release","title":"Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly","source":"Business Wire","url":"https://businesswire.com/news/home/20250811862394/en/Marea-Therapeutics-Enrolls-First-Participant-in-Phase-1-Clinical-Study-Evaluating-MAR002-for-Acromegaly"},{"date":"2025-08-04","kind":"Press release","title":"Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD","source":"BioSpace","url":"https://biospace.com/press-releases/marea-therapeutics-enrolls-first-patient-in-phase-2b-tydal-timi-78-clinical-study-evaluating-mar001-in-adults-at-risk-of-ascvd"},{"date":"2024-12-20","kind":"Press release","title":"Marea Therapeutics Expands Management Team and Board of Directors","source":"BioSpace","url":"https://biospace.com/press-releases/marea-therapeutics-expands-management-team-and-board-of-directors"},{"date":"2024-08-25","kind":"Press release","title":"Marea Therapeutics Appoints Ian Clements as Chief Financial Officer","source":"Business Wire","url":"https://businesswire.com/news/home/20240825781009/en/Marea-Therapeutics-Appoints-Ian-Clements-as-Chief-Financial-Officer"},{"date":"2024-06-19","kind":"News","title":"Marea Therapeutics Launches With $190 Million","source":"citybiz","url":"https://citybiz.co/article/569061/marea-therapeutics-launches-with-190-million/"}],"story":[{"title":"Acquired Lisata Therapeutics Acquires Marea Therapeutics; Announces Concurrent Private Placement · RTTNews","url":"https://rttnews.com/3691936/lisata-therapeutics-acquires-marea-therapeutics-announces-concurrent-private-placement.aspx"},{"title":"New executive Marea Therapeutics Appoints Ian Clements as Chief Financial Officer · Business Wire","url":"https://businesswire.com/news/home/20240825781009/en/Marea-Therapeutics-Appoints-Ian-Clements-as-Chief-Financial-Officer"}],"as_of":"2026-11-17","cite":"Marea Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/mareatx/news","html_url":"https://alion.io/company/mareatx/news","json_url":"https://alion.io/company/mareatx/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T10:15:17Z"}}